Treatment of Alzheimer's Disease subjects with expanded non-genetically modified autologous natural killer cells (SNK01): a phase I study

Table 6 ADCOMS by Subject and Visit– ITT Population

Cohort	Subject	AD Severity Stage	Baseline	Week 11/ Visit 5		Week 22/ EOS
Cohort	Subject	AD Severity Stage	Score	Score	CFB	Score	CFB
1	002	moderate	1.330	1.403	0.073	1.567	0.237
	003	moderate	1.193	1.137	-0.056	1.256	0.063
	004	mild	0.901	0.842	-0.059	1.083	0.182
	005	mild	0.700	0.550	-0.150	0.596	-0.104
2	006	severe	1.460	1.665	0.205	np
	007	mild	0.859	0.706	-0.153	0.846	-0.013
	009	severe	1.701	np		np
	011	mild	0.615	0.664	0.049	0.687	0.072
3	012	severe	1.718	1.718	0	1.718	0
	014	moderate	1.054	0.810	-0.244	0.846	-0.208
	015	mild	0.755	0.723	-0.032	0.829	0.074
Medians (IQR)			1.054 (0.755, 1.460)	0.826 (0.696, 1.469)	-0.044 (-0.151, 0.055)	0.846 (0.758, 1.412)	0.063 (-0.059, 0.128)

ISSN: 1758-9193